Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24281978 | 0.77 | NPC1 (0.33) | NPC1CNR2CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL821222 | 0.76 | TDP1 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL18944183 | 0.76 | TDP1 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL24281979 | 0.76 | TDP1 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL26201180 | 0.75 | ELANE (0.35) | NPC1CYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL26201185 | 0.74 | ELANE (0.32) | NPC1ELANEPOLBGAANPSR1 | |
| SCHEMBL14572732 | 0.72 | KDM4E (0.35) | NPC1CNR2CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL26201589 | 0.70 | ELANE (0.33) | NPC1CYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL26201200 | 0.69 | CNR2 (0.33) | NPC1CNR2CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL20243596 | 0.69 | MEN1 (0.31) | CYP1A2KMT2ACYP2D6NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | CYP3A43, PRMT8, MGMT | NPC1 3226/4885CNR2 2295/4885CYP2C19 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.